Last updated: February 4, 2026
Case Overview
Chiesi USA, Inc. filed a patent infringement lawsuit against Hikma Pharmaceuticals USA, Inc. in the District of Delaware. The case involves alleged infringement of patents related to inhalation drug delivery systems. Chiesi asserts that Hikma’s generic inhaler products infringe on its patents covering specific mechanical features and methods of delivering respiratory medication.
Litigation Timeline
- Filing Date: February 7, 2020
- Legal Basis: Patent infringement under 35 U.S.C. § 271.
- Defendant's Response: Hikma filed a motion to dismiss on October 22, 2020, asserting non-infringement and alleged invalidity of the patents.
- Claim Construction: Court issued a claim construction order on September 15, 2021.
- Summary Judgment Motions: Filed by both parties in March 2022.
- Trial Date: Initially set for March 2023, later delayed to September 2023, then to December 2023.
Patents at Issue
Chiesi alleges infringement of three patents:
- U.S. Patent No. 10,560,074: Covers a portable inhaler with specific actuator and aerosol chambers.
- U.S. Patent No. 10,702,972: Addresses a metered-dose inhaler with a particular valving system.
- U.S. Patent No. 10,769,713: Concerns a method of delivering medication via inhaler with improved dose accuracy.
Infringement Allegations
Chiesi claims Hikma’s inhalers utilize features protected by its patents, including:
- An actuator with a specific sealing mechanism.
- An aerosol delivery chamber configured for efficient dose transfer.
- A metering valving system matching the patent descriptions.
Hikma contends that its products do not infringe and challenge the validity of Chiesi’s patents based on prior art and patent scope.
Key Legal Issues
- Claim Construction: How the claims of the patents are interpreted, particularly regarding terms like "seal" and "metering chamber."
- Infringement: Whether Hikma’s products contain all elements of the asserted claims.
- Invalidity: Whether the patents are invalid due to obviousness or prior art references.
Recent Developments
- Motion to Dismiss Denied (2021): The court declined Hikma’s attempt, allowing the case to proceed to discovery.
- Inter Partes Review (IPR) Requests: Hikma filed IPR petitions with the Patent Trial and Appeal Board (PTAB), challenging the patents’ validity; decisions are pending.
- Pretrial Conference (2023): Scheduled for late 2023, focusing on trial readiness and dispositive motions.
- Settlement Discussions: Underway, but no public resolution announced.
Legal Trends and Strategy
The case reflects typical patent litigation in inhalation therapy devices, emphasizing detailed claim construction and technological distinctions. Hikma’s IPR filings indicate a broader strategy to invalidate patents through USPTO proceedings, which could significantly impact the litigation outcome.
Market and Patent Implications
Chiesi, as a patent holder, seeks to enforce its rights against generic competitors. Hikma’s challenges could weaken patent protections if successful, opening pathways for generic market entry. The case exemplifies the ongoing tension between patent enforceability and patent validity challenges in pharmaceutical device sectors.
Summary
Chiesi USA, Inc. accuses Hikma Pharmaceuticals of infringing inhalation device patents, with the case steadily progressing through pleadings, claim construction, and potential invalidity defenses. Pending PTAB decisions on IPR petitions are critical, potentially altering the litigation trajectory.
Key Takeaways
- The case hinges on claim interpretation and whether Hikma’s inhalers infringe the patents as claimed.
- Hikma’s IPR filings pose a significant threat to patent validity, possibly leading to invalidation.
- Disputes over claim scope will influence the likelihood of injunctions against Hikma’s products.
- The litigation illustrates patent enforcement strategies in the inhalation drug device market.
- The outcome may impact patent rights and market entry strategies for inhalation therapy manufacturers.
FAQs
1. What specific features are claimed as proprietary in Chiesi’s patents?
The patents claim features such as a sealing actuator, specialized aerosol chambers, and a metering valving system designed for precise dose delivery.
2. How does Hikma challenge the patents’ validity?
Hikma argues that prior art renders the patents obvious or anticipated, and that certain patent claims are overly broad or indefinite.
3. What is the significance of the PTAB’s IPR proceedings in this case?
The IPR proceedings could invalidate the patents, potentially ending the infringement claims or weakening enforcement rights.
4. What are the possible outcomes if the patents are invalidated?
Infringement claims would be dismissed or reduced, allowing Hikma to market its inhalers without patent infringement liability.
5. How does this case compare to other inhaler patent litigations?
It reflects a common pattern where patent holders enforce rights against generic challengers, often supplemented by IPR filings to undermine patent strength.
References
[1] Docket entry and case filings, District of Delaware | 1:20-cv-00484.
